A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients

The purpose of this study is to evaluate the effects of the addition of SG301 injection to pomalidomide and dexamethasone in subjects with relapsed or refractory multiple myeloma.

Trial Details

NCT ID
NCT06508983
Phase
PHASE3
Sponsor
Hangzhou Sumgen Biotech Co., Ltd.
Status
RECRUITING
Cancer Type
Relapsed/Refractory Multiple Myeloma
Interventions
  • SG301 Injection
  • SG301 placebo
  • pomalidomide
  • dexamethasone
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Luoyang, Henan, China|34.67345,112.43684
  • Zhengzhou, Henan, China|34.75778,113.64861

Key Eligibility Criteria

  • Understand and voluntarily sign the informed consent form (ICF).
  • Males and females aged 18-75 years (inclusive)
  • Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0, 1 or 2
  • Expected survival time of ≥3 months.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Relapsed/Refractory Multiple Myeloma Trials on Trialify →